AORT ARTIVION, INC.
NYSE · SEC CIK 784199 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $20.73M 46 sales by 8 insiders
- Filings on record
- 315 since 2021-08-24, latest 2026-09-11 17:28
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Mackin James P | Pres, CEO | — | $9.72M |
| Stanton Marshall S. | SVP, Clinical, MD Affair | — | $3.43M |
| Holloway Jean F | SVP, GC | — | $2.54M |
| Davis John E | Chief Commercial Off | — | $1.75M |
| GREEN ANDREW M | SVP, Regulatory, Quality | — | $1.43M |
| Horton Amy | VP, CAO | — | $870.1K |
| Berry Lance A | EVP, COO, CFO, Treas | — | $803.2K |
| Hoff Elizabeth A | Dir | — | $189.4K |
| SEMEDO ANTHONY B. | Dir | — | — |
| Borgstrom Marna P | Dir | — | — |
Transactions 430
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-05-27 | 2025-05-22 | AORT | ACKERMAN THOMAS F | Dir | A - Grant | $0.00 | +6,325 | 149.9K | +4% | $0 | |
| 2025-05-21 | 2025-05-21 | AORT | Holloway Jean F | SVP, GC | S - Sale | $29.00 | -9,926 | 187.3K | -5% | -$287.9K | |
| M | 2025-05-12 | 2025-05-09 | AORT | Stanton Marshall S. | SVP, Clinical, MD Affair | S - Sale | $29.13 | -10.5K | 110.1K | -9% | -$307.3K |
| D | 2025-03-12 | 2025-03-11 | AORT | Davis John E | Chief Commercial Off | S - Sale+OE | $23.61 | -15.1K | 208.8K | -7% | -$356.5K |
| D | 2025-03-12 | 2025-03-11 | AORT | Davis John E | Chief Commercial Off | M - OptEx | $21.55 | +15.9K | 223.9K | +8% | +$342.9K |
| D | 2025-03-12 | 2025-03-11 | AORT | Holloway Jean F | SVP, GC | M - OptEx | $21.55 | +19.1K | 215.2K | +10% | +$411.4K |
| D | 2025-03-12 | 2025-03-11 | AORT | Holloway Jean F | SVP, GC | S - Sale+OE | $23.61 | -18.0K | 197.2K | -8% | -$425.5K |
| 2025-03-10 | 2025-03-06 | AORT | Berry Lance A | CFO, Executive VP | S - Sale | $24.80 | -4,909 | 153.4K | -3% | -$121.7K | |
| 2025-03-10 | 2025-03-06 | AORT | Berry Lance A | CFO, Executive VP | A - Grant | $0.00 | +48.1K | 158.3K | +44% | $0 | |
| 2025-03-10 | 2025-03-06 | AORT | Horton Amy | VP, CAO | S - Sale | $24.80 | -1,048 | 146.7K | -0.7% | -$26.0K | |
| 2025-03-10 | 2025-03-06 | AORT | Horton Amy | VP, CAO | A - Grant | $0.00 | +10.3K | 147.7K | +7% | $0 | |
| 2025-03-10 | 2025-03-06 | AORT | Davis John E | Chief Commercial Off | S - Sale | $24.80 | -2,618 | 208.0K | -1% | -$64.9K | |
| 2025-03-10 | 2025-03-06 | AORT | Davis John E | Chief Commercial Off | A - Grant | $0.00 | +25.7K | 210.6K | +14% | $0 | |
| 2025-03-10 | 2025-03-06 | AORT | Holloway Jean F | SVP, GC | A - Grant | $0.00 | +25.5K | 198.2K | +15% | $0 | |
| 2025-03-10 | 2025-03-06 | AORT | Holloway Jean F | SVP, GC | S - Sale | $24.80 | -2,124 | 196.1K | -1% | -$52.7K | |
| 2025-03-10 | 2025-03-06 | AORT | Stanton Marshall S. | SVP, Clinical, MD Affair | A - Grant | $0.00 | +19.2K | 117.5K | +20% | $0 | |
| 2025-03-10 | 2025-03-06 | AORT | Stanton Marshall S. | SVP, Clinical, MD Affair | S - Sale | $24.80 | -1,603 | 115.9K | -1% | -$39.8K | |
| DM | 2025-03-10 | 2025-03-06 | AORT | Mackin James P | Pres, CEO | S - Sale+OE | $24.77 | -88.4K | 860.4K | -9% | -$2.19M |
| D | 2025-03-10 | 2025-03-06 | AORT | Mackin James P | Pres, CEO | M - OptEx | $21.55 | +75.6K | 936.0K | +9% | +$1.63M |
| D | 2025-03-10 | 2025-03-06 | AORT | Mackin James P | Pres, CEO | A - Grant | $0.00 | +115.7K | 878.1K | +15% | $0 |
| 2025-03-06 | 2025-03-05 | AORT | Holloway Jean F | SVP, GC | S - Sale | $25.29 | -472 | 172.7K | -0.3% | -$11.9K | |
| I | 2025-03-05 | 2025-03-05 | AORT | SEMEDO ANTHONY B. | Dir | P - Purchase | $25.25 | +600 | 600 | New | +$15.2K |
| 2025-03-05 | 2025-03-05 | AORT | SEMEDO ANTHONY B. | Dir | P - Purchase | $25.33 | +1,500 | 35.7K | +4% | +$38.0K | |
| 2025-03-04 | 2025-02-28 | AORT | Stanton Marshall S. | SVP, Clinical, MD Affair | A - Grant | $0.00 | +18.4K | 98.2K | +23% | $0 | |
| 2025-03-04 | 2025-02-28 | AORT | Holloway Jean F | SVP, GC | A - Grant | $0.00 | +23.4K | 173.2K | +16% | $0 | |
| 2025-03-04 | 2025-02-28 | AORT | Horton Amy | VP, CAO | A - Grant | $0.00 | +6,297 | 137.4K | +5% | $0 | |
| 2025-03-04 | 2025-02-28 | AORT | Berry Lance A | CFO, Executive VP | A - Grant | $0.00 | +34.4K | 110.2K | +45% | $0 | |
| 2025-03-04 | 2025-02-28 | AORT | Mackin James P | Pres, CEO | A - Grant | $0.00 | +98.5K | 762.4K | +15% | $0 | |
| 2025-03-04 | 2025-02-28 | AORT | Davis John E | Chief Commercial Off | A - Grant | $0.00 | +24.3K | 184.9K | +15% | $0 | |
| M | 2025-02-26 | 2025-02-24 | AORT | Davis John E | Chief Commercial Off | S - Sale | $27.31 | -6,457 | 163.7K | -4% | -$176.3K |
| 2025-02-26 | 2025-02-24 | AORT | Berry Lance A | CFO, Executive VP | S - Sale | $27.31 | -3,259 | 75.8K | -4% | -$89.0K | |
| M | 2025-02-26 | 2025-02-24 | AORT | Holloway Jean F | SVP, GC | S - Sale | $27.31 | -5,335 | 149.8K | -3% | -$145.7K |
| M | 2025-02-26 | 2025-02-24 | AORT | Mackin James P | Pres, CEO | S - Sale | $27.31 | -42.2K | 668.8K | -6% | -$1.15M |
| M | 2025-02-26 | 2025-02-24 | AORT | Stanton Marshall S. | SVP, Clinical, MD Affair | S - Sale | $27.31 | -4,687 | 79.8K | -6% | -$128.0K |
| M | 2025-02-26 | 2025-02-24 | AORT | Horton Amy | VP, CAO | S - Sale | $27.31 | -3,323 | 131.9K | -2% | -$90.8K |
| 2024-12-13 | 2024-12-12 | AORT | Horton Amy | VP, CAO | G - Gift | $0.00 | -1,100 | 134.5K | -0.8% | $0 | |
| M | 2024-12-12 | 2024-12-11 | AORT | Holloway Jean F | SVP, GC | S - Sale | $30.12 | -8,070 | 153.9K | -5% | -$243.1K |
| A | 2024-12-10 | 2024-12-06 | AORT | Horton Amy | VP, CAO | S - Sale | $29.05 | -4,425 | 135.6K | -3% | -$128.5K |
| 2024-12-09 | 2024-12-06 | AORT | Horton Amy | VP, CAO | S - Sale | $29.66 | -4,329 | 135.7K | -3% | -$128.4K | |
| 2024-12-04 | 2024-12-04 | AORT | GREEN ANDREW M | VP Regulatory | S - Sale | $30.00 | -7,618 | 33.5K | -19% | -$228.5K | |
| D | 2024-10-02 | 2024-10-01 | AORT | Horton Amy | VP, CAO | M - OptEx | $21.55 | +12.4K | 152.4K | +9% | +$267.9K |
| D | 2024-10-02 | 2024-10-01 | AORT | Horton Amy | VP, CAO | S - Sale+OE | $26.18 | -12.4K | 140.0K | -8% | -$325.4K |
| 2024-08-27 | 2024-08-26 | AORT | Holloway Jean F | SVP, GC | S - Sale | $26.55 | -3,167 | 161.9K | -2% | -$84.1K | |
| M | 2024-08-19 | 2024-08-16 | AORT | Getz Matthew A | VP, Human Resources | S - Sale | $25.31 | -9,420 | 36.7K | -20% | -$238.4K |
| 2024-08-16 | 2024-08-15 | AORT | Holloway Jean F | SVP, GC | S - Sale | $25.76 | -2,383 | 165.1K | -1% | -$61.4K | |
| 2024-08-15 | 2024-08-13 | AORT | SEMEDO ANTHONY B. | Dir | S - Sale | $24.99 | -9,709 | 34.2K | -22% | -$242.6K | |
| 2024-06-03 | 2024-05-30 | AORT | ACKERMAN THOMAS F | Dir | A - Grant | $0.00 | +6,289 | 143.6K | +5% | $0 | |
| 2024-06-03 | 2024-05-30 | AORT | SEMEDO ANTHONY B. | Dir | A - Grant | $0.00 | +6,289 | 43.9K | +17% | $0 | |
| 2024-06-03 | 2024-05-30 | AORT | Bullock James | Dir | A - Grant | $0.00 | +6,289 | 62.3K | +11% | $0 | |
| 2024-06-03 | 2024-05-30 | AORT | Borgstrom Marna P | Dir | A - Grant | $0.00 | +6,289 | 42.8K | +17% | $0 | |
| 2024-06-03 | 2024-05-30 | AORT | BEVEVINO DANIEL J | Dir | A - Grant | $0.00 | +6,289 | 143.7K | +5% | $0 | |
| 2024-06-03 | 2024-05-30 | AORT | Hoff Elizabeth A | Dir | A - Grant | $0.00 | +6,289 | 25.1K | +33% | $0 | |
| 2024-06-03 | 2024-05-30 | AORT | Burbank Jeffrey H | Dir | A - Grant | $0.00 | +6,289 | 47.5K | +15% | $0 | |
| 2024-06-03 | 2024-05-30 | AORT | Salveson Jon W | Dir | A - Grant | $0.00 | +6,289 | 123.5K | +5% | $0 | |
| 2024-05-13 | 2024-05-10 | AORT | Holloway Jean F | SVP, GC | S - Sale | $23.42 | -1,250 | 167.5K | -0.7% | -$29.3K | |
| 2024-05-10 | 2024-05-09 | AORT | Holloway Jean F | SVP, GC | S - Sale | $23.79 | -979 | 168.7K | -0.6% | -$23.3K | |
| 2024-03-21 | 2024-03-20 | AORT | Stanton Marshall S. | SVP, Clinical, MD Affair | S - Sale | $20.39 | -2,183 | 83.3K | -3% | -$44.5K | |
| 2024-03-18 | 2024-03-15 | AORT | GREEN ANDREW M | VP Regulatory | S - Sale | $20.00 | -1,462 | 41.1K | -3% | -$29.2K | |
| 2024-03-15 | 2024-03-14 | AORT | GREEN ANDREW M | VP Regulatory | S - Sale | $20.00 | -3,994 | 42.6K | -9% | -$79.9K | |
| A | 2024-03-14 | 2024-03-01 | AORT | Horton Amy | VP, CAO | A - Grant | $0.00 | +3,578 | 141.1K | +3% | $0 |
| A | 2024-03-14 | 2024-03-05 | AORT | Horton Amy | VP, CAO | S - Sale | $18.72 | -1,152 | 140.0K | -0.8% | -$21.6K |
| MA | 2024-03-14 | 2024-02-23 | AORT | Stanton Marshall S. | SVP, Clinical, MD Affair | A - Grant | $0.00 | +16.0K | 83.2K | +24% | $0 |
| MA | 2024-03-14 | 2024-02-26 | AORT | Stanton Marshall S. | SVP, Clinical, MD Affair | S - Sale | $20.27 | -3,007 | 72.5K | -4% | -$61.0K |
| 2024-03-14 | 2024-03-12 | AORT | Getz Matthew A | VP, Human Resources | S - Sale | $19.94 | -5,000 | 43.5K | -10% | -$99.7K | |
| A | 2024-03-14 | 2024-02-27 | AORT | Horton Amy | VP, CAO | S - Sale | $19.83 | -325 | 137.6K | -0.2% | -$6,445 |
| MA | 2024-03-14 | 2024-02-23 | AORT | Davis John E | Chief Commercial Off | A - Grant | $0.00 | +18.1K | 164.4K | +12% | $0 |
| MA | 2024-03-14 | 2024-02-26 | AORT | Davis John E | Chief Commercial Off | S - Sale | $20.27 | -3,461 | 151.7K | -2% | -$70.2K |
| A | 2024-03-14 | 2024-03-05 | AORT | Holloway Jean F | SVP, GC | S - Sale | $18.72 | -2,380 | 169.7K | -1% | -$44.6K |
| A | 2024-03-14 | 2024-03-01 | AORT | Holloway Jean F | SVP, GC | A - Grant | $0.00 | +5,724 | 172.1K | +3% | $0 |
| MA | 2024-03-14 | 2024-02-23 | AORT | Getz Matthew A | VP, Human Resources | A - Grant | $0.00 | +10.8K | 47.6K | +29% | $0 |
| MA | 2024-03-14 | 2024-02-26 | AORT | Getz Matthew A | VP, Human Resources | S - Sale | $20.27 | -2,280 | 46.4K | -5% | -$46.2K |
| A | 2024-03-14 | 2024-02-27 | AORT | Holloway Jean F | SVP, GC | S - Sale | $19.83 | -485 | 166.4K | -0.3% | -$9,618 |
| MA | 2024-03-14 | 2024-02-23 | AORT | Holloway Jean F | SVP, GC | A - Grant | $0.00 | +18.2K | 168.4K | +12% | $0 |
| MA | 2024-03-14 | 2024-02-26 | AORT | Holloway Jean F | SVP, GC | S - Sale | $20.27 | -2,838 | 155.6K | -2% | -$57.5K |
| MA | 2024-03-14 | 2024-02-23 | AORT | Mackin James P | Pres, CEO | A - Grant | $0.00 | +99.1K | 709.2K | +16% | $0 |
| MA | 2024-03-14 | 2024-02-26 | AORT | Mackin James P | Pres, CEO | S - Sale | $20.27 | -30.8K | 696.3K | -4% | -$625.0K |
| A | 2024-03-14 | 2024-02-27 | AORT | GREEN ANDREW M | VP Regulatory | S - Sale | $19.83 | -421 | 44.2K | -0.9% | -$8,348 |
| A | 2024-03-14 | 2024-03-05 | AORT | Getz Matthew A | VP, Human Resources | S - Sale | $18.72 | -1,157 | 48.5K | -2% | -$21.7K |
| A | 2024-03-14 | 2024-03-01 | AORT | Getz Matthew A | VP, Human Resources | A - Grant | $0.00 | +3,578 | 49.7K | +8% | $0 |
| A | 2024-03-14 | 2024-02-27 | AORT | Getz Matthew A | VP, Human Resources | S - Sale | $19.83 | -325 | 46.1K | -0.7% | -$6,445 |
| MA | 2024-03-14 | 2024-02-23 | AORT | GREEN ANDREW M | VP Regulatory | A - Grant | $0.00 | +10.3K | 45.8K | +29% | $0 |
| MA | 2024-03-14 | 2024-02-26 | AORT | GREEN ANDREW M | VP Regulatory | S - Sale | $20.27 | -2,367 | 38.9K | -6% | -$48.0K |
| A | 2024-03-14 | 2024-03-01 | AORT | Maney Rochelle L. | VP, Quality | A - Grant | $0.00 | +3,578 | 47.7K | +8% | $0 |
| A | 2024-03-14 | 2024-03-05 | AORT | Maney Rochelle L. | VP, Quality | S - Sale | $18.72 | -1,157 | 46.6K | -2% | -$21.7K |
| A | 2024-03-14 | 2024-02-27 | AORT | Stanton Marshall S. | SVP, Clinical, MD Affair | S - Sale | $19.83 | -465 | 81.3K | -0.6% | -$9,221 |
| A | 2024-03-14 | 2024-03-05 | AORT | GREEN ANDREW M | VP Regulatory | S - Sale | $18.72 | -1,160 | 46.6K | -2% | -$21.7K |
| A | 2024-03-14 | 2024-03-01 | AORT | GREEN ANDREW M | VP Regulatory | A - Grant | $0.00 | +3,578 | 47.7K | +8% | $0 |
| A | 2024-03-14 | 2024-03-05 | AORT | Davis John E | Chief Commercial Off | S - Sale | $18.72 | -2,022 | 165.7K | -1% | -$37.9K |
| A | 2024-03-14 | 2024-03-01 | AORT | Davis John E | Chief Commercial Off | A - Grant | $0.00 | +5,724 | 167.7K | +4% | $0 |
| A | 2024-03-14 | 2024-02-27 | AORT | Maney Rochelle L. | VP, Quality | S - Sale | $19.83 | -370 | 44.1K | -0.8% | -$7,337 |
| A | 2024-03-14 | 2024-03-01 | AORT | Stanton Marshall S. | SVP, Clinical, MD Affair | S - Sale | $18.72 | -1,506 | 85.5K | -2% | -$28.2K |
| A | 2024-03-14 | 2024-03-01 | AORT | Stanton Marshall S. | SVP, Clinical, MD Affair | A - Grant | $0.00 | +5,724 | 87.0K | +7% | $0 |
| MA | 2024-03-14 | 2024-02-23 | AORT | Horton Amy | VP, CAO | A - Grant | $0.00 | +9,784 | 138.9K | +8% | $0 |
| MA | 2024-03-14 | 2024-02-26 | AORT | Horton Amy | VP, CAO | S - Sale | $20.27 | -2,134 | 137.9K | -2% | -$43.3K |
| A | 2024-03-14 | 2024-02-27 | AORT | Mackin James P | Pres, CEO | S - Sale | $19.83 | -4,837 | 691.4K | -0.7% | -$95.9K |
| A | 2024-03-14 | 2024-02-27 | AORT | Davis John E | Chief Commercial Off | S - Sale | $19.83 | -584 | 162.0K | -0.4% | -$11.6K |
| MA | 2024-03-14 | 2024-02-23 | AORT | Maney Rochelle L. | VP, Quality | A - Grant | $0.00 | +9,784 | 45.6K | +27% | $0 |
| MA | 2024-03-14 | 2024-02-26 | AORT | Maney Rochelle L. | VP, Quality | S - Sale | $20.27 | -2,282 | 44.5K | -5% | -$46.3K |
| A | 2024-03-14 | 2024-03-05 | AORT | Mackin James P | Pres, CEO | S - Sale | $18.72 | -14.0K | 706.0K | -2% | -$262.0K |
| A | 2024-03-14 | 2024-03-01 | AORT | Mackin James P | Pres, CEO | A - Grant | $0.00 | +28.6K | 720.0K | +4% | $0 |
Purchase Sale Sale after option exercise All abbreviations